Observational studyFrontiers in cellular and infection microbiology2026
Clinical characteristics, microbiological landscape, and severity-stratified management of pyogenic spondylitis: a retrospective cohort study.
Observational study in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize the clinical, radiological, and microbiological features of pyogenic spondylitis (PS) and to describe outcomes observed within a severity-stratified real-world management pathway integrating antimicrobial therapy, stabilization, debridement, and fusion according to structural instability and neurological risk. Methods: We conducted a retrospective observational cohort study of 149 patients with PS treated at Ningxia Medical University General Hospital between January 2015 and December 2023. Patients were retrospectively grouped according to baseline structural severity, neurological status, and the management strategy actually used in routine care: Group A, antimicrobial therapy plus external immobilization (n = 48); Group B, posterior fixation and fusion plus antimicrobial therapy (n = 57); and Group C, posterior fixation with debridement and fusion via posterior and/or anterior approaches plus antimicrobial therapy (n = 44). Clinical characteristics, microbiological findings, inflammatory markers, VAS, ODI, Cobb angle, perioperative variables, complications, and endpoint-defined recovery were analyzed. Principal-component analysis and adjusted response models were prespecified as exploratory analyses. Results: The three groups represented distinct severity strata, ranging from structurally stable disease to destructive disease with neurological compromise. Final diagnostic adjudication identified 73 microbiologically confirmed cases, whereas the prespecified patient-level yield analysis was limited to a 66-case interpretable pretreatment subset, within which positivity was lower in Group C than in Groups A and B (40.0% vs 82.4% and 84.2%, respectively; P = 0.001). At the specimen level, 95 bacterial isolate records were summarized, and Conclusions: In this retrospective real-world cohort, a severity-stratified management pathway for PS was feasible and showed coherent microbiological, inflammatory, functional, and radiological recovery patterns within each clinical stratum. These findings support pragmatic escalation according to structural instability and neurological risk, but they should not be interpreted as comparative evidence of treatment superiority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.